In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
After finishing at $145.93 in the prior trading day, Insmed Inc (NASDAQ: INSM) closed at $145.79, down -0.10%. In other words, the price has decreased by -$0.10 from its previous closing price. On the day, 1.61 million shares were traded. INSM stock price reached its highest trading level at $147.09 during the session, while it also had its lowest trading level at $144.93.
Ratios:
Our goal is to gain a better understanding of INSM by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.33 and its Current Ratio is at 6.68. In the meantime, Its Debt-to-Equity ratio is 0.59 whereas as Long-Term Debt/Eq ratio is at 0.59.
On August 13, 2025, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight but kept the price unchanged to $126. On May 13, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $105.Jefferies initiated its Buy rating on May 13, 2025, with a $105 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 02 ’25 when Smith Michael Alexander sold 24,272 shares for $143.89 per share. The transaction valued at 3,492,378 led to the insider holds 54,902 shares of the business.
Flammer Martina M.D. sold 186,648 shares of INSM for $26,941,272 on Sep 02 ’25. The Chief Medical Officer now owns 83,111 shares after completing the transaction at $144.34 per share. On Sep 02 ’25, another insider, Flammer Martina M.D., who serves as the Officer of the company, bought 186,648 shares for $144.31 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INSM now has a Market Capitalization of 30845919232 and an Enterprise Value of 29728198656. For the stock, the TTM Price-to-Sale (P/S) ratio is 77.40 while its Price-to-Book (P/B) ratio in mrq is 24.63. Its current Enterprise Value per Revenue stands at 74.674 whereas that against EBITDA is -32.403.
Stock Price History:
The Beta on a monthly basis for INSM is 1.03, which has changed by 0.952719 over the last 52 weeks, in comparison to a change of 0.17089343 over the same period for the S&P500. Over the past 52 weeks, INSM has reached a high of $149.08, while it has fallen to a 52-week low of $60.40. The 50-Day Moving Average of the stock is 23.89%, while the 200-Day Moving Average is calculated to be 68.83%.
Shares Statistics:
The stock has traded on average 3.64M shares per day over the past 3-months and 2202780 shares per day over the last 10 days, according to various share statistics. A total of 211.11M shares are outstanding, with a floating share count of 207.22M. Insiders hold about 2.20% of the company’s shares, while institutions hold 99.33% stake in the company. Shares short for INSM as of 1756425600 were 10563132 with a Short Ratio of 2.90, compared to 1753920000 on 9537045. Therefore, it implies a Short% of Shares Outstanding of 10563132 and a Short% of Float of 5.53.
Earnings Estimates
A detailed examination of Insmed Inc (INSM) is currently in progress, with 13.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$1.18, with high estimates of -$0.93 and low estimates of -$1.94.
Analysts are recommending an EPS of between -$5.29 and -$6.08 for the fiscal current year, implying an average EPS of -$5.55. EPS for the following year is -$3.96, with 12.0 analysts recommending between -$2.37 and -$9.14.
Revenue Estimates
15 analysts predict $113.89M in revenue for the current quarter. It ranges from a high estimate of $121.97M to a low estimate of $106M. As of the current estimate, Insmed Inc’s year-ago sales were $93.42MFor the next quarter, 15 analysts are estimating revenue of $155.39M. There is a high estimate of $176.11M for the next quarter, whereas the lowest estimate is $136M.
A total of 17 analysts have provided revenue estimates for INSM’s current fiscal year. The highest revenue estimate was $498.14M, while the lowest revenue estimate was $446M, resulting in an average revenue estimate of $470.64M. In the same quarter a year ago, actual revenue was $363.71MBased on 15 analysts’ estimates, the company’s revenue will be $1.07B in the next fiscal year. The high estimate is $1.44B and the low estimate is $884.87M.
